<DOC>
	<DOCNO>NCT00003727</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Combining chemotherapy peripheral stem cell transplant immunotherapy may allow doctor give high dos chemotherapy drug kill cancer cell . Biological therapy use different way stimulate immune system stop cancer cell grow . PURPOSE : This phase II trial study give chemotherapy together peripheral stem cell transplant follow immunotherapy see well work treat patient chronic phase chronic myelogenous leukemia .</brief_summary>
	<brief_title>Chemotherapy Peripheral Stem Cell Transplantation Followed Immunotherapy Treating Patients With Chronic Myelogenous Leukemia</brief_title>
	<detailed_description>OBJECTIVES : - Determine feasibility ex vivo expansion reinfusion autologous CD4+ T cell interferon therapy high-dose chemotherapy CD34-selected autologous peripheral blood stem cell rescue patient chronic phase chronic myelogenous leukemia ( CML ) . - Determine frequency hematologic , cytogenetic , molecular remission CML follow infusion ex vivo expand T cell . OUTLINE : Patients undergo mononuclear cell leukapheresis obtain T cell ex-vivo expansion , preferably receive interferon alfa subcutaneously ( SC ) daily therapeutic trial . At least 1 month interferon stop , mobilization chemotherapy administer . Patients receive cyclophosphamide IV 12 hour day 0 , etoposide IV 2 hour day 1 , sargramostim ( GM-CSF ) SC day 3 4 , filgrastim ( G-CSF ) SC begin day 5 . Peripheral blood stem cell ( PBSC ) collect leukapheresis blood cell count recover . Approximately 2-3 week later , high-dose chemotherapy begin . Patients receive gemcitabine IV 100 minute day -5 , carmustine IV 2 hour day -2 , follow 6 hour later gemcitabine IV , melphalan IV 20 minute day -1 . CD34 select PBSCs infuse day 0 , least 18 hour melphalan administration . Patients receive GM-CSF SC begin day 1 continue blood cell count recover . Patients receive ex vivo expand autologous T cell day 14 autotransplantation . Interferon alfa administer three time week start 3 month transplantation . Patients receive expand T cell , without high-dose chemotherapy autotransplantation , show response 3 month , may proceed autotransplantation follow second ex vivo expand T-cell infusion . Patients follow 1 , 2 , 3 , 6 , 9 , 12 month , every 6 month thereafter . PROJECTED ACCRUAL : A total 7-22 patient accrue study .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Carmustine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis chronic myelogenous leukemia base clinical feature molecular evidence bcr/abl gene rearrangement First second chronic phase time stem cell collection Ineligible allogeneic transplantation Should receive interferon alfa ( IFNA ) without lowdose cytarabine least 36 month autotransplantation meet one follow condition : After 3 month IFNA , hematologic response partial less poor clinical feature present diagnosis After 6 month IFNA , hematologic response partial complete ( 100 % Ph+ ) poor clinical feature present diagnosis After 9 12 month IFNA , cytogenetic response occur ( 100 % Ph+ ) , regardless pretreatment clinical feature After least 12 month IFNA ( 2 separate test , 3 month apart ) , minor cytogenetic response ( 3590 % Ph+ ) occur , eligible ex vivo expand autologous T cell ( without highdose chemotherapy autografting ) highdose therapy plus autograph physician ' discretion After least 12 month IFNA ( 2 test , 3 month apart ) , major complete cytogenetic response ( 034 % Ph+ ) occur , eligible ex vivo expand autologous T cell ( without highdose chemotherapy autografting ) After least 18 month IFNA , complete cytogenetic response ( 0 % Ph+ ) occur remain positive BCR/ABL gene rearrangement eligible ex vivo expand autologous T cell ( without highdose chemotherapy autografting ) Unsatisfactory response prior STI571 allow ( regardless prior IFNA ) PATIENT CHARACTERISTICS : Age : Not specify Performance status : ECOG 02 Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Bilirubin great 2 time upper limit normal ( ULN ) ( unless due Gilbert 's disease ) AST ALT great 2 time ULN ( unless liver involvement CML ) Renal : Creatinine great 2.5 mg/dL Cardiovascular : LVEF least 45 % ( low allow significant functional impairment ) Pulmonary : FEV_1 , FVC , DLCO least 50 % predict Other : No active infection require IV antibiotic HIV negative Not pregnant nursing Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : See Disease Characteristics At least 1 month since prior interferon Chemotherapy : At least 1 week since hydroxyurea leukapheresis Endocrine therapy : Not specify Radiotherapy : Not specify Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2009</verification_date>
	<keyword>relapse chronic myelogenous leukemia</keyword>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
	<keyword>Philadelphia chromosome positive chronic myelogenous leukemia</keyword>
	<keyword>Philadelphia chromosome negative chronic myelogenous leukemia</keyword>
	<keyword>childhood chronic myelogenous leukemia</keyword>
</DOC>